Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group.
Qi SN, Li YX, Specht L, Oguchi M, Tsang R, Ng A, Suh CO, Ricardi U, Mac Manus M, Dabaja B, Yahalom J.
Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1064-1081. doi: 10.1016/j.ijrobp.2021.02.011. Epub 2021 Feb 11.
PMID:33581262
Extranodal T- and NK-cell lymphomas.
de Leval L, Feldman AL, Pileri S, Nakamura S, Gaulard P.
Virchows Arch. 2023 Jan;482(1):245-264. doi: 10.1007/s00428-022-03434-0. Epub 2022 Nov 7.
Hematol Oncol. 2023 Apr;41(2):221-229. doi: 10.1002/hon.2944. Epub 2021 Dec 9.
PMID:34731509
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R.
J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11.
PMID:21990393
Diagnosis and management of extranodal NK/T cell lymphoma nasal type.